Matthew Herper on Muck Rack

Matthew Herper Verified

New York
Senior Editor — Forbes
As seen in:  Forbes

Forbes reporter covering science and medicine

It's Time For The GOP To Embrace The Obamacare Exchanges

forbes.com — Here's a wake-up call to conservatives: Unless you change something fast, your response to the Affordable Care Act will go down in history as a series of tactical errors that created a gigantic government mandate while simultaneously betraying your own principles. The Supreme Court's resounding 6-3 rejection of King v.

Hope And Hype For New Type Of Antidepressant

forbes.com — Two brothers - one an entrepreneur, the other a Columbia University psychiatrist - are claiming today that a new combination of experimental medicines may prevent suicidal thoughts in people with bipolar disorder. The drug, D-cycloserine, was originally developed as a treatment for tuberculosis. Now, the brothers, Jonathan (CEO) and Daniel (scientist) [...]

This Drug To Treat Double Chins Is a Perfect Fit For Botox-Maker Allergan. But Is It Too Pricey?

forbes.com — One thing about Allergan chief executive Brent Saunders is he doesn't waste much time. After all, he was personally involved in setting up $97 billion worth of deals last year. The $66 billion acquisition of the company that used to be called Allergan by Saunders' outfit, then called Actavis, closed in March.

Why The FDA's Trans Fat Ban Is A Triumph Of Good Government

forbes.com — The U.S. Food and Drug Administration today announced that it is banning companies from preparing foods with trans fats, artificially manufactured fats that have been shown to increase the risk of heart attacks and strokes. "It's about time, " says Kevin Marzon, Chief of Cardiology at Winthrop-University Hospital in Mineola, N.Y.

FDA: Drug Companies Routinely Hide The Reasons Their Drugs Are Rejected From Investors

forbes.com — Seven times between August 11, 2008, and June 27, 2013, the Food and Drug Administration declined to approve a new medicine, in part, because patients were more likely to die when taking the drug than in a control group. Yet only one of those companies told investors - and the [...]

Study On Preventing College Rape Shows Us How We Should Run The World

forbes.com — There's a great study published today in the New England Journal of Medicine on a program for teaching college women how to behave in order to lower their risk of being sexually assaulted. The women who were assigned to take the four-part, small group training sessions were half as likely to [...]

Live Blog: FDA Panel For Amgen's Cholesterol Drug Repatha

forbes.com — All day, a panel of experts has been discussing for Amgen's Repatha, a new drug developed based on genetic data that dramatically lowers cholesterol. Yesterday, a nearly identical panel voted that a similar drug developed by Regeneron and Sanofi should be approved, but for a very narrow use. Now we're getting [...]

How The New Cholesterol Drugs From Amgen And Regeneron Could Still Be Blockbusters

forbes.com — A tepid recommendation from an expert advisory panel could limit the sales of new cholesterol drugs, but they could still become $1 billion products in the near term, and generate as much as $15 billion five years from now. Last night, Praluent, an experimental cholesterol drug from Regeneron and Sanofi, received a [...]

The Luckiest Guy In The Drug Business

forbes.com — How weird have things gotten in the drug industry? Ask Roger Newton, who led the development of Pfizer 's Lipitor, the world's biggest drug. Then, 10 years ago, he left to found a biotech and sold it to Pfizer for more than a billion dollars.

Federal Panel Recommends Approving High-Powered Cholesterol Shot With Cautions

forbes.com — A panel of doctors convened to advise the Food and Drug Administrated voted that a new, high-powered cholesterol shot called Praluent should be approved, but was nervous about allowing a broad swath of patients to take the medicine, instead suggesting that its use be narrowed until large studies proves it prevents [...]
More Articles →
Jul 07, 2015

Go $CVS RT @charlesornstein Up in smoke: CVS Health Quits U.S. Chamber Over Stance on Smoking nyti.ms/1Ux2aU8

Jul 07, 2015

RT @CharlesMBlow: Paula, baby, just let it go. Let everything go. Delete Twitter. Throw your phone in a deep fryer. Just walk away... twitter.com/grubstreet/sta…

Jul 07, 2015

Why We Need to Talk More About Mental Illness in Tech and Business <-- must read by @jeffbercovici inc.com/jeff-bercovici…

Jul 07, 2015

No Crying In Biotech: Managing Short Sellers From Strength onforb.es/1CgOCWK by @dbsable

Jul 07, 2015

RT @daviesbj: @juliaoftoronto @matthewherper Appendix 2 explanation of LD bias- while interesting - doesn't mean that mortality effect is impossible later

Jul 07, 2015

Eli Lilly preps a familiar case for FDA review of a marginal cancer drug - FierceBiotech: fiercebiotech.com/story/eli-lill…

Jul 07, 2015

RT @JohnTuckerPhD: @juliaoftoronto @matthewherper Do low BC screening rates correlate wtih poor cause of death reporting?Implausible # of countries w/ 0 deaths

Email Matthew by joining Muck Rack



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile